| LIQUIDIA CORP. DL-,001 |
| USA |
| Gesundheit |
| US53635D2027 / A2JRNS |
| LT4 (Frankfurt) / LQDA (NASDAQ) |
| FRA:LT4, ETR:LT4, LT4:GR, NASDAQ:LQDA |
| - |
| https://liquidia.com/ |
|
Liquidia Corporation is a biopharmaceutical company focused on therapies for rare cardiopulmonary diseases, primarily in the United States. The company develops, manufactures, and commercializes treatments aimed at addressing unmet patient needs in p..
>Volltext.. |
| 4659.03 Mio. EUR |
| 4626.18 Mio. EUR |
| 247.49 Mio. EUR |
| 40.49 Mio. EUR |
| 19.16 Mio. EUR |
| 0.21 EUR |
| 158.79 Mio. EUR |
| 191.41 Mio. EUR |
| - |
| 1.49 |
| 1807.06% |
| - |
| - |
| - |
| - |
| 6 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 37.687.117 USD. |
| LIQUIDIA |
| 27.05.26 |